Persistent reductions in OCS use in patients with severe, OCS dependent asthma treated with dupilumab: LIBERTY ASTHMA TRAVERSE study

Mark Gurnell, Christian Domingo, Klaus F Rabe, Andrew Menzies-Gow, David Price, Guy Brusselle, Michael E Wechsler, Changming Xia, Michel Djandji, Rebecca Gall, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz, Shahid Siddiqui

Research output: Contribution to conferenceAbstractpeer-review

Original languageEnglish
Publication statusAccepted/In press - 8 Aug 2022
EventWorld Allergy Congress 2022 - Hilton Bomonti Istanbul Hotel & Conference Center, Istanbul, Turkey
Duration: 13 Oct 202215 Oct 2022


ConferenceWorld Allergy Congress 2022
Abbreviated titleWAC 2022 Istanbul
Internet address

Bibliographical note

Acknowledgments and funding sources
Data first presented at the American Thoracic Society - 118th International Conference (ATS 2022); San Francisco, CA, USA, May 13-18, 2022. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Anthony Aggidis, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline.

Cite this